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Abstract
Targeting mitochondrial energy metabolism is a novel approach in cancer research and can
be traced back to the description of the Warburg effect. Dichloroacetate, a controversially
discussed subject of many studies in cancer research, is a pyruvate dehydrogenase kinase
inhibitor. Dichloroacetate causes metabolic changes in cancerous glycolysis towards oxida-
tive phosphorylation via indirect activation of pyruvate dehydrogenase in mitochondria.
Canine mammary cancer is frequently diagnosed but after therapy prognosis still remains
poor. In this study, canine mammary carcinoma, adenoma and non-neoplastic mammary
gland cell lines were treated using 10 mM Dichloroacetate. The effect on cell number, lac-
tate release and PDH expression and cell respiration was investigated. Further, the effect
on apoptosis and several apoptotic proteins, proliferation, and microRNA expression was
evaluated. Dichloroacetate was found to reduce cell proliferation without inducing apoptosis
in all examined cell lines.
Introduction
Mammary tumors are the most frequent neoplasia in intact female dogs and often accompa-
nied with high recurrence and metastasis rates [1]. In veterinary medicine as well as human
medicine a surgical intervention is indicated often with subsequent chemotherapy [1]. In
advanced tumor disease the prognosis still remains poor [1] therefore new alternatives for che-
motherapy have to be investigated.
The Warburg effect was characterized in the early 1920s by Otto Warburg and describes the
metabolic energy production of most cancer cells which rely on aerobic glycolysis in presence
of oxygen [2, 3]. Hypoxia in early cancer transformation results in expression of hypoxia
inducible factor 1 alpha (HIF-1α) activating pyruvate dehydrogenase kinase (PDK), a pyruvate
dehydrogenase (PDH) inhibiting enzyme [4]. PDH inhibition prevents incorporation of pyru-
vate in mitochondria and is related with cytoplasmic metabolization of pyruvate to lactate [4].
Compensation of negative energy output during glycolysis occurs with increased expression of
glycose transporters induced by HIF-1α [5]. Glycolysis contains several advantages for cancer
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progression such as lactic acidosis allowing tumor growth due to damage of extracellular
matrix and increased cell mobility [6]. Decreased cell respiration leads to lower production of
reactive oxygen species (ROS) in mitochondria as well as decreased DNA damage and enables
apoptosis resistance [7, 8]. The glycolytic feature of cancer cells might offer a selective thera-
peutic target sparing treatment of non-cancerous cells [3].
Dichloroacetate (DCA) is a pyruvate dehydrogenase kinase inhibitor [9] and thus enhances
the flux of pyruvate into the mitochondria by indirect activation of pyruvate dehydrogenase
[10]. By reason of occurring glycolytic profile in cancer and penetration of most tissues after
oral administration [10, 11], DCA appears to be a proficient strategic therapeutic target in
oncology [11]. The last decades, DCA was used as lactate lowering drug in human with con-
genital mitochondrial dysfunction in phase III studies [12, 13] and became a controversially
discussed subject in cancer research. Michelakis et al. found that DCA normalized mitochon-
drial function and decreased cancer growth in vitro and pointed out that non-cancerous cells
were not affected [14]. Dunbar et al. reported that DCA was well tolerated and feasible in a
phase I trial in patients suffering from recurrent glioblastomas [15] but in contrast, another
study had to be cancelled due to severe neuropathies [16]. DCA in human mammary tumors
showed inconsistent results. Feuerecker et al. reported higher viability and proliferation in
human SrBr3 cells after DCA treatment [17] whereas Sun et al. determined inhibited cell
growth in several mammary cancer cell lines [18]. Higher apoptotic resistance [19] as well as
increased mitochondrial depolarization was reported in human MCF-7 cells [11].
In previous studies we investigated the effect of DCA on canine prostate adenocarcinomas
and transitional cell carcinomas in vitro [20] and found that DCA has anti-proliferative effects
on canine prostate and bladder tissue derived cell lines. Until now, there is no data available
analyzing the effects of DCA on canine mammary tumors. DCA seems to be well tolerated in
dogs with lactic acidosis [21] and other studies concerning pharmacokinetic effects [22, 23].
For evaluation of anticancer drug efficacy in preclinical experiments cell lines represent
important in vitro models to gain more information of cancer independent sensitivity [24–26].
In this study several cell lines derived from canine mammary tissue were used in order to eval-
uate DCA efficiency.
This is the first study evaluating the effect of 10 mM DCA on canine mammary carcinoma
as well as canine mammary adenoma cell lines in comparison to a non-cancerous mammary
gland derived cell line and a non-treated control. Therefore, the influence on cell counts, via-
bility, apoptosis, mitochondrial respiration and proliferation was examined. Furthermore, the
expression of microRNA involved in proliferation and apoptosis was determined.
Materials and methods
Cell lines
Four cell lines derived from different mammary tissues were used for experiments. MTH53A
(non-neoplastic mammary gland), MTH52C (mammary carcinoma) and ZMTH3 (mammary
adenoma) were transfected with SV-40 and routinely maintained in the Small Animal Clinic,
University of Veterinary Medicine, Hannover, Germany. SV-40 transfection was performed
to achieve immortalization as primary cultures derived from mammary tissue (MTH53A,
MTH52C and ZMTH3) showed limited proliferation capacity. DT14/06T (mammary carci-
noma) was established by continuous cultivation in the Small Animal Clinic, University of
Veterinary Medicine Hannover, Germany. The cell lines were classified after pathohistological
examination of the primary tissue. All tissues used for cell line establishment were collected as
part of routine mastectomy and with the owner’s permission. Therefore according to German
standards, ethical approval was not required.
Effect of dichloroacetate in canine mammary cell lines
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Cell culture
All cell lines were routinely maintained in 25 cm2 culture flasks (TPP, Faust Lab Science, Klett-
gau, Gemany) with medium 199 (GibcoTM, Thermofisher Scientific, Darmstadt, Germany)
containing 10% fetal calf serum (HyClone1, Thermofisher Scientific), 2% penicillin-strep-
tomycin (Biochrom, Berlin, Germany) and incubated at 37˚C and 5% CO2 in humidified
atmosphere. At 85% confluency cells were trypsinized with TrypLETM Express (GibcoTM,
Thermofisher Scientific) and were splitted 1:2.
DCA application
Cells used in experiments were exposed to 10 mM DCA over 48 hours and cultured with 10 ml
medium in 75 cm2 flasks (TPP, Faust Lab Science). DCA was diluted in deionized water and
filter-sterilized after pH modulation to 7.4 with NaOH. All cell lines were cultured without
DCA and used as non-treated control respectively. The concentration of 10 mM DCA was
chosen in order to allow comparability with previous human [27] and canine [20] in vitro stud-
ies. Furthermore, this dosage is applied in an explorative study setting.
Cell counting
After washing with PBS to remove dead cells and trypsinization with TrypLETM Express (Gib-
coTM, Thermofisher Scientific) cell number was counted with an automated CellometerTM
Auto T4 (Nexcelom Bioscience, Lawrence, MA, USA) and compared with untreated control.
Cells were washed with PBS, centrifuged at 1000 rpm for 10 minutes (Biochrom) and stored at
-80˚C for further examinations (quantitative RT-PCR and protein analysis).
Lactate levels
Lactate release in media was performed by colorimetric determination with Cobas1 C311
(Hitachi, Tokio, Japan). Therefore growth media from cell culture was centrifuged at 1000
rpm for 10 minutes to remove floating cells and debris and 1.3 ml were removed to a sodium
fluoride vessel (Sarstedt, Nu¨mbrecht, Germany). To eliminate influences of phenol red and
fetal calf serum, medium was used as negative control and deducted from measurements. Fur-
ther the lactate content was normalized to intracellular protein concentration to prevent influ-
ences of cell numbers and volume. Protein concentration was assessed with PierceTM BCA
Assay (Thermofisher Scientific) as described in manufacturer´s instructions.
Metabolic activity
Depending on each cell line 3000–6000 cells were seeded in a 96-well-plate (Falcon, Corning,
Amsterdam, The Netherlands) with 200 μl medium 199, 10% fetal calf serum, 2% penicillin-
streptomycin, 10 mM DCA and incubated at 37˚C and 5% humidified CO2. Measurements
were performed every 24 hours for four days. Therefore medium was replaced and 20 μl MTT
(CellTiter961 Aqueous One Solution Assay, Promega, Mannheim, Germany) was added and
incubated for two hours at 37˚C in the dark. Absorbance was determined with a Synergy2
plate reader (BioTek, Bad Friedrichshall, Germany) and data were analyzed with Gen5TM 1.11
Software (BioTek). Absorbance was reduced by media negative control and in addition nor-
malized to non-treated new seeded cells.
Flow cytometry
Apoptosis and quantity of dead cells was analyzed with Annexin FITC and Sytox labeling
(Annexin V-FITC Detection Kit Plus, PromoCell, Heidelberg, Germany). Therefore 105 cells
Effect of dichloroacetate in canine mammary cell lines
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were cultured in a 6-well-plate (TPP, Faust Lab Science) as described above. After 48 hours
following 10 mM DCA exposure, cells were trypsinized and centrifuged together with super-
natant containing non-adherent and dead cells at 1000 rpm for 6 minutes. Cell pellet was
resuspended in 500 μl assay buffer and staining was performed as described in manufacturer’s
protocol. 104 events were counted with BD FACScaliburTM (BD Biosciences, Heidelberg, Ger-
many) and CellQuestTM Pro 6.0 software (BD Biosciences). Annexin and Sytox were detected
in FL-1. Data analysis was performed with FlowJo Version 10.0.8r1 (FlowJo, Ashland, OR,
USA). Gates were determined based on positive controls (cells permeabilized with Saponin)
and negative controls of each cell line (non-treated viable cells).
RNA isolation and quantitative RT-PCR
Isolation of total RNA was performed with 106 cells using the NucleoSpin Small RNA Kit
(Macherey Nagel, Du¨ren, Germany) as described in manufacturer’s protocol. 35 ng total RNA
was used for cDNA synthesis using Taqman1 MicroRNA Reverse Transkription Kit (Applied
BiosystemsTM, Thermofisher Scientific) according to manufacturer´s instructions. Following
cycle conditions were used: 30 minutes 16˚C, 30 minutes 42˚C, 5 minutes 85˚C. Relative quantifi-
cation of microRNA expression of treated cells in comparison to untreated control was performed
with Eppendorff realplex4 Cycler (Eppendorf, Wesseling-Berzdorf, Germany) using 1.33 μl cDNA
in a total volume of 20 μl containing TaqMan1 Universal Master Mix NoAmpErase1 UNG
(Applied BiosystemsTM, Thermofisher Scientific) and TaqMan1 MicroRNA assays for Mir141
(ID 245445_mat), Mir145 (ID 002278), Mir375 (ID 000564) purchased from Thermofisher Scien-
tific. Procedure was maintained as manufacturer´s protocol conducting following conditions:
95˚C for 10 minutes subsequently 40 cycles of 95˚C for 15 seconds and 60˚C for 60 seconds. Data
were normalized to the reference gene RNU6B (ID 001093) and analysis was performed using
Rest2009 (Qiagen, Hilden, Germany). Samples with Ct-values>35 were excluded from analysis.
Luminex magnetic bead analysis
Samples for protein expression analysis were prepared as specified in manufacturer´s protocol
and measurements were performed with xMAP1 Luminex Bead Technology using a Lumi-
nex 200TM instrument (Luminex Corporation, Hertogenbosch, The Netherlands) and pro-
cessed with xPONENT 3.1 software (Luminex Corporation). Additionally, samples for PDH
measurements were filtered with centrifugal ultrafree filter units with a pore size of 0.65 μm
(Merck Millipore) at 7000 rpm for 4 minutes. Values with MFI< background MFI + 2 x stan-
dard deviation were excluded from analysis. Quantitation of survivin was performed with Pro-
cartaPlex Human Survivin Simplex Kit (eBioscience, Frankfurt am Main, Germany) using cell
culture supernatant as described in manufacturer´s protocol. Survivin values were normalized
to protein concentration (Pierce BCA Assay, Thermofisher Scientific). Total PDH, PDH-P
and apoptotic proteins (BAD and JNK) were analyzed with multiplex assays from Merck Milli-
pore (Multi-species PDH Complex Magnetic Bead Panel and 7-Plex Early Apoptosis Magnetic
Bead Kit, Darmstadt, Germany). For protein evaluation a total protein amount of 10 ng
(PDH-P) or rather 25 ng (apoptotic proteins JNK and BAD) was used, which was determined
with Pierce BCA Assay according to manufacturer’s instruction (Thermofisher Scientific).
Mitochondrial ROS production
Mitochondrial ROS production as indirect marker for mitochondrial activity was determined
by staining of mitochondrial derived ROS using 4 μM MitoSox (Invitrogen, Thermofisher Sci-
entific) for 15 minutes. Cells were grown on 8-well μ-dishes (Ibidi, Martinsried, Germany)
treated with 10 mM DCA for 48 hours. After fixation with 4% paraformaldehyde, μ-slides
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were washed with Hank´s Balanced Salt Solution (HBSS) containing calcium and magnesium.
After staining cell nuclei were labeled with DAPI (dilution of 1:1000, Sigma Aldrich GmbH)
for 5 minutes. Fluorescence imaging was performed with an inverted confocal laser scanning
microscope (Eclipse TE2000-E, Nikon, Du¨sseldorf, Germany) using a 60x water immersion
objective (Nikon). Images were taken with EZ-C1 1.80 software (Nikon). The excitation
occurred with a diode laser at 408 nm (DAPI) and with a helium/neon laser at 543 nm (Mito-
Sox). Total cell fluorescence of MitoSox deducting background was analyzed with ImageJ and
normalized to cell counts.
Mitochondrial ATP-synthesis
Mitochondrial respiration was directly shown by measuring cellular ATP synthesis. The cell lines
were seeded (5000 cells/well) as triplicate in a 96-opaque-well plate (Greiner Bio-One) with 100 μl
medium 199, 10% fetal calf serum, 2% streptomycin-penicillin, 10 mM DCA and incubated at
37˚C humidified CO2. After 48 hours incubation 100 μl ATP-solution (CellTiter-Glo1 2.0 Assay,
Promega) was added. Following 10 minutes incubation at room temperature, luminescence mea-
surement was performed with Synergy2 Plate Reader (BioTek). In order to normalize the data
with the respective cell numbers, cells were counted in a simultaneously performed experiment by
flow cytometry (MACSQuant Analyzer 10, Miltenyi Biotek, Bergisch Gladbach, Germany).
Immunofluorescence staining of Ki67 and TUNEL
Cultivation, fixation and washing were performed as described above. After permeabilization
using 0.2% Triton X-100 for 20 minutes, cells were exposed overnight to a canine specific rab-
bit-polyclonal Ki67 antibody (dilution of 1:150; Life Technologies, Thermofisher Scientific).
For labeling, a monoclonal anti-rabbit Alexa Fluor1 555 antibody (Cell Signaling Technology,
Leiden, The Netherlands) was incubated for 1 hour (1:250) and cells were counterstained with
DAPI (1:1000) for 5 minutes. Fluorescence imaging protocol was the same as described above.
Total cell fluorescence was established as described above. For TUNEL staining Apoptag Fluo-
rescein Direct Kit (Merck Millipore) was performed as manufacturer´s instructions. The exci-
tation occurred with an argonlaser at 488 nm and imaging was performed as described above.
The amount of TUNEL positive cells was evaluated.
Western blot
Protein expression analysis was performed with Immunoblotting (Western Blot) as descri-
bed in detail by Wagner et al. [28]. The protein concentration was determined using Pierce
BCA Assay (Thermofisher Scientific) and for electrophoresis 60 μg protein of each sample
was used. The PVDF membrane was incubated overnight at 4˚C with a canine specific poly-
clonal primary antibody anti-rabbit anti-PDK-1 (1:1000, ABIN2499649, antibodies-online,
Aachen, Germany) or a canine specific polyclonal anti-rabbit anti-PDK-3 antibody (1:500,
ABIN278250, antibodies-online). Afterwards, the PVDF membrane was incubated with a sec-
ondary antibody anti-rabbit IgG, AP Conjugate for 2 hours (Promega, Mannheim, Germany).
A canine specific monoclonal anti-mouse anti-GAPDH antibody (Abcam, Cambridge, United
Kingdom) was used as loading control.
Statistical analysis
Statistical analysis of data was performed with SAS software 7.1 (SAS Institute Inc., Cary, NC,
USA). For comparison of two means, two-tailed t-test was used. The confidence value was set
to 5% (p<0.05) and was considered statistically significant.
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Results
DCA reduces cell number
Following 48 hours DCA treatment (10 mM) the cell numbers of both mammary carcinoma
cell lines MTH52C (p = 0.0171) and DT14/06T (p<0.0001) decreased significantly in compari-
son to non-treated control. A comparable significant effect was observed in the mammary
adenoma cell line ZMTH3 (p = 0.0131) and could also be constituted in the non-cancerous
mammary gland derived cell line MTH53A (p = 0.0039). Although MTH53A showed decreas-
ing cell numbers, a statistically significant difference between the mammary carcinoma cell
line DT14/06T (p = 0.0140) and the non-cancerous cell line MTH53A was present. No differ-
ence was observed between MTH53A and the adenoma derived cell line ZMTH3 or the mam-
mary carcinoma derived cell line MTH52C (Fig 1).
DCA affects proliferation
The proliferation, assessed by detection of the proliferation marker Ki67, decreased signifi-
cantly in all mammary cell lines with exception of the non-neoplastic mammary gland derived
cell line MTH53A in comparison to non-treated control and further a significant decrease in
proliferation can be observed within comparison of MTH53A and the other cell lines. No dif-
ference was assessed between neoplastic cell lines (Fig 2).
Decreased lactate release after DCA treatment
In comparison to negative control DCA reduced the lactate release into the media in all exam-
ined cell lines except in the benign mammary adenoma cell line ZMTH3 (p = 0.1218). No sta-
tistical difference was observed within non-cancerous and neoplastic cell lines (Fig 3).
DCA did not alter PDK expression
In order to assess the effect of DCA on PDK expression, protein analysis of PDK-1 and PDK-3
was performed. As shown in Fig 4 PDK-1 expression was visible in all examined cell lines
(untreated and treated) at 48 kDa. In comparison to untreated control no changes could be
determined. The protein PDK-3 (47 kDa) was not detectable in all cell lines (supplementary
files, S2 Fig).
Fig 1. Influence of 10 mM DCA on mammary cell lines after 48 hours. Statistical significant reduction of
cell number was observed in all cell lines. Significant difference in cell number between MTH53A and
mammary carcinoma DT14/06T was observed. Data is shown as mean ± standard deviation (SD), n3 and
are presented as relative cell numbers in comparison to the respective corresponding untreated control (%).
Control values were set to 100%. Statistical analysis was performed with two-tailed t-test, *p<0.05, **p<0.01,
***p<0.001.
https://doi.org/10.1371/journal.pone.0178744.g001
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Decreased PDH phosphorylation after DCA treatment
Phosphorylated PDH (PDH-P) and thus inactive PDH was measured with Luminex Magnetic
Bead technology to evaluate whether DCA has an effect on pyruvate oxidation. After normali-
zation to total PDH expression phosphorylated PDH at Ser232 decreased significantly in all
cell lines whereas PDH-P at Ser293 was reduced only in the mammary carcinoma DT14/06T
(p = 0.0445) (Fig 5). The mammary adenoma cell line ZMTH3 and mammary carcinoma cell
line MTH52C showed apparent decreased average values, but due to variations between exper-
iments no significance was observed. MTH53A showed no reduction of PDH-P at Ser293 in
comparison to untreated control. With consideration of PDH-P at Ser300 a significant decrease
is apparent between mammary carcinoma derived cell lines MTH52C (p = 0.0263), DT14/06T
(p = 0.0282) and non-treated control. ZMTH3 showed visible tendency of PDH-P reduction
Fig 2. Impact of 10 mM DCA on proliferation of mammary cell lines after 48 hours determined with fluorescence microscopy.
(A-H) Images showing fluorescence of Ki67 (red) and DAPI (blue). In comparison to non-treated control (A,C,E,G) amount of Ki67 is
reduced in all DCA treated cell lines (B,D,F,H) except in MTH53A (B). Statistical significant reduction of Ki67 was observed in ZMTH3,
MTH52C and DT14/06T in comparison to non-treated control and non-neoplastic tissue derived cell line MTH53A. No significant
decrease in proliferation could be determined in within neoplastic cell lines (I). Data are shown as mean ± SD, n3 and are presented
as relative proliferation in comparison to untreated control (%). Control was set to 100%. Statistical analysis was performed with two-
tailed t-test; *p<0.05, **p<0.01, ***p<0.001. (A) MTH53A control; (B) MTH53A+DCA; (C) ZMTH3 control; (D) ZMTH3+DCA; (E)
MTH52C control; (F) MTH52C+DCA; (G) DT14/06T control; (H) DT14/06T+DCA; (I) relative proliferation.
https://doi.org/10.1371/journal.pone.0178744.g002
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but did not reach significance (p = 0.0852). No reduction was apparent in all PDH-P residues
between MTH53A and neoplastic cell lines.
DCA affects mitochondrial respiration
Mitochondrial respiration was evaluated via indirect measurement of mitochondrial derived
ROS. As shown in Fig 6 the production of mitochondrial derived ROS increased slightly in
MTH53A (p = 0.1386), DT14/06T (p = 0.1519) and significantly in MTH52C (p = 0.0359). In
contrast the benign cell line ZMTH3 showed significantly decreased ROS production and thus
decreased mitochondrial activity (p = 0.0243). A statistical significant difference is apparent by
comparison of MTH53A and ZMTH3 (p = 0.0178). Additionally mitochondrial respiration
was directly assessed by cellular ATP synthesis. A significant increased ATP production after
DCA exposure in all cell lines was shown (Fig 7). No apparent difference was observed
between the evaluated cell lines.
DCA did not affect apoptosis
After 48 hours DCA treatment, viability analysis with flow cytometry revealed no changes in
apoptosis and amount of dead cells in MTH53A, ZMTH3 and DT14/06T (Fig 8A). In
MTH52C the percentage of apoptotic cells (p = 0.0256) decreased significantly after DCA
exposure and accompanied with significantly increased viability (p = 0.0472).
Fig 3. Effect of 10 mM DCA on lactate release of mammary cell lines after 48 hours. In comparison to
untreated control significant reduction of lactate production was proved in all cell lines except the benign
mammary adenoma (ZMTH3). No significant difference was evaluated between MTH53A and the other cell
lines. Data are shown as mean ± SD, n3 and are presented as relative lactate content in comparison to
untreated control (%). Control was set to 100%. Statistical analysis was performed with two-tailed t-test,
*p<0.05, **p<0.01, ***p<0.001.
https://doi.org/10.1371/journal.pone.0178744.g003
Fig 4. Effect of 10 mM DCA on PDK-1 expression after 48 hours. Western Blot analysis of PDK-1
expression in MTH53A, MTH52C, ZMTH3 and DT14/06T. All cell lines showed positivity for PDK-1 and
GAPDH but no changes in PDK-1 expression was detectable between untreated and DCA exposed cells in
any of the evaluated cell lines. GAPDH was used as loading control.
https://doi.org/10.1371/journal.pone.0178744.g004
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To determine if trypsinization caused negative effects, apoptosis was evaluated with
TUNEL method via fluorescence microscopy. No difference in number of TUNEL positive
cells was evaluated in any of these cell lines (S1 Fig).
Further, two proteins (c-jun N-terminal kinases and Bcl-2-Antagonist-of-cell-death)
involved in apoptosis were evaluated. The protein expression was performed with Luminex
Magnetic Bead technology. After 48 hours of DCA treatment, the phosphorylated and thus
activated c-jun N-terminated kinases (JNK) decreased significantly in MTH53A (p = 0.0046),
ZMTH3 (p = 0.0228) and MTH52C (p = 0.0131). The inverse case was observed in mammary
carcinoma cell line DT14/06T (p = 0.0121) presenting significantly increased active JNK
expression (Fig 8B).
The phosphorylated and thus inactive form of Bcl-2-Antagonist-of-cell-death (BAD)
showed significantly increased values in all neoplastic cell lines. In MTH53A (p = 0.2340) no
difference was detectable (Fig 8C).
DCA decreased survivin expression
Decreased survivin expression is apparent in all cell lines but significance is present in cell line
DT14/06T (p = 0.0125) in comparison to untreated control as well as in comparison to non-
neoplastic mammary gland derived cell line MTH53A (p = 0.0200) (Fig 9).
Metabolic activity following 96 hours continuous DCA treatment
The metabolic activity as reference for proliferation and viability was assessed during 96 hours
ongoing DCA treatment (Fig 10). After 96 hours the non-neoplastic cell line MTH53A and the
mammary carcinoma cell line DT14/06T showed no significant differences in metabolic activ-
ity compared to untreated control. Merely ZMTH3 showed significant decreased metabolic
activity starting at 24 hours whereas MTH52C displayed significantly decreased MTT-values
after 24 hours. Following DCA treatment metabolic activity in MTH52C converge to non-
treated control.
Fig 5. Effect of 10 mM DCA on PDH phosphorylation at three different residues after 48 hours
treatment. Data was assessed with Luminex Magnetic Bead technology. PDH-P at Ser232 decreased
significantly in all cell lines. Residue Ser293 showed no significant response to DCA treatment except in cell
line DT14/06T. The third phosphorylation site Ser300 has decreased values in carcinoma cell lines but not in
non-neoplastic mammary gland derived cell line MTH53A and benign cell line ZMTH3. Data are shown as
mean ± SD, n3 and are presented as relative PDH-P values in comparison to untreated control (%). Control
was set to 100%. Statistical analysis was performed with two-tailed t-test, *p<0.05, **p<0.01, ***p<0.001.
https://doi.org/10.1371/journal.pone.0178744.g005
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MicroRNA expression after DCA exposure
Three microRNAs involved in apoptosis and proliferation were analyzed with quantitative
RT-PCR. miR-145 was detectable only in the mammary carcinoma cell line DT14/06T (Fig
11A) and showed no significant difference after DCA treatment (p = 0.1025), the other cell
lines showed basal expression under limit of detection and were excluded from analysis.
Regarding miR-375, significant changes after DCA treatment revealed in the cell line ZMTH3
(p = 0.0086), whereas MTH53A and MTH52C showed no modifications in miR expression
(Fig 11B). miR-141 expression was below the limit of detection in all cell lines and was ex-
cluded from analysis due to Ct-values >35.
Fig 6. Influence of 10 mM DCA on mitochondrial activity in mammary cell lines after 48 hours. (A-H) Fluorescence of
mitochondrial derived ROS (red) and counterstained cell nuclei (DAPI, blue). (I) In comparison to untreated control significant
improvement of mitochondrial activity was observed in mammary carcinoma cell line MTH52C. A visible but insignificant increase was
observable in the mammary carcinoma cell line DT14/06T and non-cancerous mammary gland derived cell line MTH53A. The
adenoma cell line ZMTH3 showed significantly decreased mitochondrial activity in comparison to untreated control and non-
cancerous cell line MTH53A. No significant difference was evaluated between MTH53A and the other cell lines. Data are shown as
mean ± SD, n3 and are presented as relative fluorescence (mitochondrial activity) in comparison to untreated control (%). Control
was set to 100%. Statistical analysis was performed with two-tailed t-test, *p<0.05, **p<0.01, ***p<0.001. (A) MTH53A control; (B)
MTH53A+DCA; (C) ZMTH3 control; (D) ZMTH3+DCA; (E) MTH52C control; (F) MTH52C+DCA; (G) DT14/06T control; (H) DT14/06T
+DCA; (I) relative mitochondrial activity.
https://doi.org/10.1371/journal.pone.0178744.g006
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Discussion
The initial aim of this study was to determine which metabolic processes occur in canine
mammary gland derived cell lines during DCA exposure and if DCA might be beneficial for
cancer treatment in dogs bearing mammary gland neoplasia. The results presented illustrate
that DCA has anti-proliferative effects on cell growth which is shown in decreased cell number
and reduction of the proliferation marker Ki67 expression. The growth inhibiting effect was
likewise observed in several human studies [29–32] including mammary neoplastic and non-
neoplastic cell lines [11, 18, 33] as well as in canine prostate and bladder cancer cell lines [20].
The decreased expression of Ki67 indicates a delayed cell division resulting in changes of
expression of several proteins involved in differentiation, as described by Vella et al. [34]. The
verification of the proteomic changes leading to the observed alteration cell division would
require broad proteome analysis. In comparison to canine prostate adenocarcinoma and
transitional cell carcinoma cell lines [20], the mammary gland derived cell lines showed a
decreased responsiveness to DCA compared to transitional cell carcinoma cell lines. However,
the observed response was similar to effects reported for canine prostate adenocarcinoma cell
lines. In contrast to human cell lines, no significant difference was observed between the non-
neoplastic mammary gland derived cell line and neoplastic cell lines [11, 18, 35].
Due to increased cellular respiration and thus mitochondrial ROS production, it is hypoth-
esized that DCA induces mitochondrial dependent apoptosis by release of cytochrome c and
activation of several apoptosis proteins [11]. However, the mammary carcinoma cell line
MTH52C showed increased mitochondrial derived ROS production but no increase in apo-
ptosis was observed in the examined cell lines. Instead a decreased apoptosis and increased via-
bility after DCA treatment was observed in MTH52C. This result is similar to observations in
human mammary and neuroblastoma cell lines [17]. The observed effect could be a result of
protective hormesis a phenomenon reported to describe the effect of low dosages of toxic sub-
stances resulting in higher viability [36]. Further it should be noted that not all ROS are effi-
cient enough to induce apoptosis [37]. Despite ROS increase, it might be possible that not
enough apoptosis inducing ROS mediators, e. g. hydrogen peroxide or hypochloric acid [37],
are produced during DCA treatment. Significant decreased values in active JNK protein were
Fig 7. Influence of DCA on cellular ATP production in mammary cell lines after 48 hours. In comparison
to untreated control significant enhancement of ATP-production was observed in all cell lines. No difference
was detectable between non-neoplastic mammary gland derived cell line MTH53A and neoplastic tissue
derived cell lines. Data are shown as mean ± SD, n3 and are presented as relative ATP-production
(mitochondrial respiration) in comparison to untreated control (%). Control was set to 100%. Statistical
analysis was performed with two-tailed t-test, *p<0.05, **p<0.01, ***p<0.001.
https://doi.org/10.1371/journal.pone.0178744.g007
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observed in all cell lines with exception of DT14/06T which showed significantly increased
activated JNK protein. Also BAD, which was determined as inactivated protein increased
significantly in all cell lines. Merely MTH53A showed no effect after DCA treatment. The
increased active form of JNK in the mammary carcinoma cell line DT14/06T could not be ver-
ified by flow cytometry and TUNEL method. Therefore it has to be suggested that active JNK,
a cellular kinase with multiple targets and effects [38], is possibly not sufficient for apoptosis
induction or has other non-apoptotic but transcriptional functions in this cell line. The meta-
bolic activity, as indicator for cell viability, did not indicate a decrease of values in all cell lines
after 96 hours and is consistent with data provided from flow cytometry. Stockwin et al.
reported that high concentrations of DCA are required for apoptosis induction [19]. The same
extent was noticed in canine prostate adenocarcinoma and transitional cell carcinoma cell
lines [20] and several human cancer entities as well as in mammary cancer using dosages
between 0.5 and 40 mM DCA [17, 18, 35, 37, 39–41], whereas Bonnet et al. was able to induce
apoptosis with 0.5 mM DCA in human MCF-7 cells. Further Babu et al. reported that SLC5A8
transporters are required for membrane transportation of DCA [35]. SLC5A8 is silenced in
many cancer tissues as well as in mammary cancer, so that DCA might not accumulate in
Fig 8. Effect of 10 mM DCA on protein expression in mammary cell lines after 48 hours. In comparison to negative control, significant
decrease in JNK expression was observed in all cell lines except DT14/06T which showed increased JNK values. Significantly increased BAD
expression was observed in all cell lines except MTH53A. Data are shown as mean ± SD, n3 and are presented as relative mean in comparison
to untreated control (%). Control was set to 100%. Statistical analysis was performed with two-tailed t-test, *p<0.05, **p<0.01, ***p<0.001. (A)
Apoptotic and dead cells in flow cytometry; (B) relative expression of JNK; (C) relative expression of BAD.
https://doi.org/10.1371/journal.pone.0178744.g008
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mammalian cells and apoptosis was not induced with 1 mM DCA [35]. The same cancer cell
lines expressing SLC5A8 transporters undergo apoptosis when treated with 1 mM DCA [35].
Different SLC5A8 expression in cancer cell lines would declare why apoptosis is apparent
inconsistently.
Fig 9. Effect of 10 mM DCA on survivin production in several mammary cell lines after 48 hours.
Significant reduction of survivin expression was observed in DT14/06T in comparison to untreated control
and MTH53A. Data are shown as mean ± SD, n = 3 and are presented as relative survivin expression in
comparison to untreated control (%). Control was set to 100%. Statistical analysis was performed with two-
tailed t-test, *p<0.05, **p<0.01, ***p<0.001.
https://doi.org/10.1371/journal.pone.0178744.g009
Fig 10. Effect of 10 mM DCA on metabolic activity after 48 hours. In comparison to untreated control no significant reduction metabolic activity
was observed in MTH53A (A) and DT14/06T (D). ZMTH3 (B) showed significantly reduced metabolic activity after 48 hours and MTH52C after 24
hours (C). Data are shown as mean ± SD, n = 3 and are presented as relative metabolic activity in comparison to untreated control (%). Control was
set to 100%. Statistical analysis was performed with two-tailed t-test, *p<0.05, **p<0.01, ***p<0.001. (A) MTH53A; (B) ZMTH3; (C) MTH52C; (D)
DT14/06T.
https://doi.org/10.1371/journal.pone.0178744.g010
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Apart from this, survivin expression, an apoptosis inhibitor and proliferation promotor
[42, 43], showed slight but insignificant decreasing values (with exception of the mammary
carcinoma derived cell line DT14/06T) following DCA treatment and supports the hypothesis
that DCA has no pro-apoptotic effects on canine mammary cancer cells. These results are
divergent to canine prostate adenocarcinoma and transitional cell carcinoma cell lines, which
showed reduced survivin expression. Nevertheless a supportive anti-proliferative effect in
mammary gland derived cell lines might be possible. In case of the cell line DT14/06T the
decreased survivin expression might have anti-proliferating effect but seems to be too low to
induce apoptosis.
DCA, a known PDK inhibitor, shifted the energy production from glycolysis towards nor-
mal cellular respiration with glucose oxidation [9]. This is illustrated by decreased lactate
release, reduction in PDH phosphorylation and increased ATP-production and mitochondrial
respiration, respectively. The results suggest that PDH phosphorylation at Ser232 and Ser300
appear to be the most important metabolic modulation in canine PDH regulation. This sup-
ports the assumption of Rardin et al., that PDH phosphorylation at Ser232 is not limited to
heart tissue [44]. In contrast to studies in humans, Ser293 phosphorylation was not significantly
affected by DCA [29, 30]. Ser293 is reported to be phosphorylated rapidly by PDK, especially
isoform 2 [44], indicating that DCA might not influence all PDK isoforms equally in dogs. The
data provided demonstrate a shift towards normal cellular respiration which might declare the
anti-proliferative effect. Further the PDK-1 and PDK-3 expression was also analyzed to evalu-
ate, if changes in PDH phosphorylation were caused by decreased PDK expression. As the pro-
vided data show no changes neither in PDK-1 nor in PDK-3 expression was observed. This
data supports the findings, that DCA indirectly activates PDH and thus promotes cellular res-
piration towards glucose oxidation. Due a lack of canine specific PDK-2 and PDK-4 antibod-
ies, no statement regarding these two isoforms can be drawn. A different expression of PDK-2
or PDK-4 due to DCA treatment appears to be improbable.
In order to evaluate the effect of DCA on cell division and apoptosis, miR-141, miR-145
and miR-375, often deregulated in cancer [45–47], were analyzed. MiR-145 is reported to be a
tumor suppressor and usually downregulated in mammary breast cancer tissues [48, 49]. The
used dose of DCA had no effect on miR-145 expression neither in benign nor in malign mam-
mary tumors. Thus, a general miR-145 effect in the herein analyzed canine mammary tissue
Fig 11. Effect of 10 mM DCA on miR expression after 48 hours. In comparison to untreated control no significant changes in
miR-145 was proved. Regarding miR-375, a significant increase was observed in ZMTH3. Data are shown as mean ± SD, n = 3
and are presented as relative miR expression in comparison to untreated control. Ct-values were analyzed with Rest2009 and
statistical analysis was performed with two-tailed t-test, *p<0.05, **p<0.01, ***p<0.001. (A) miR-145 expression of DT14/06T;
(B) miR-375 expression.
https://doi.org/10.1371/journal.pone.0178744.g011
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derived cell lines appears unlikely. MiR-375 was significantly upregulated (1.5 fold) in mam-
mary adenoma cell line, which may indicate that proliferation may be influenced by miR-375.
It has to be considered, that this can also occur due to biological variations within experiments.
Ward et al. showed, that upregulation of miR-375 could sensitize mammary cancer cells to
Tamoxifen [50]. Nevertheless, Tamoxifen was reported to induce adverse effects in dogs [51],
a sensitization to other cytotoxic components might be beneficial, if DCA is able to alter miR-
375 expression. For miR-141, no changes were observed due to basal expression under limit of
detection and exclusion from analysis.
In comparison to human mammary cancer cell lines following DCA treatment, canine
mammary cell lines are almost consistent [18, 41]. DCA has anti-proliferative effects on canine
mammary neoplasia cell lines including non-neoplastic mammary gland derived cells, but no
apoptosis inducing properties. Further glycolytic property was inverted towards glucose oxida-
tion as shown in human mammary cancer [11]. In contrast to canine prostate adenocarcinoma
and transitional cell carcinoma cell lines, cell lines derived from mammary gland tissue
showed also an anti-proliferative effect with no apoptosis induction. However, these cell lines
appear to be more resistant regarding cell number and proliferation, survivin expression and
miR-expression. Merely changes in lactate production, PDH phosphorylation and thus cell
respiration are comparable to both canine cancer entities examined by Harting et al. [20].
Further the dose of 10 mM DCA is clinically not achievable in vivo without severe side
effects. But these data indicate that DCA might be supportive in sensitization of cancer cells to
other chemotherapeutics [52]. Further a post-surgical therapy with drug releasing inlays
implanted in the surgical area could be beneficial to achieve higher local concentrations of
DCA to treat remaining cancer cells [53].
Supporting information
S1 Fig. Percentage of TUNEL positive cells (apoptotic) after DCA exposure determined
with fluorescence microscopy. In comparison to non-treated control, no changes in apoptosis
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not detectable in all cell lines. GAPDH and α-tubulin were used as loading control.
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